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Abstract Human immunodeficiency virus (HIV) infection is currently incurable, due to the
persistence of latently infected cells. The ‘shock and kill’ approach to a cure proposes to eliminate
this reservoir via transcriptional activation of latent proviruses, enabling direct or indirect killing of
infected cells. Currently available latency-reversing agents (LRAs) have however proven ineffective.
To understand why, we used a novel HIV reporter strain in primary CD4+ T cells and determined
which latently infected cells are reactivatable by current candidate LRAs. Remarkably, none of
these agents reactivated more than 5% of cells carrying a latent provirus. Sequencing analysis of
reactivatable vs. non-reactivatable populations revealed that the integration sites were
distinguishable in terms of chromatin functional states. Our findings challenge the feasibility of
‘shock and kill’, and suggest the need to explore other strategies to control the latent HIV
reservoir.
DOI: https://doi.org/10.7554/eLife.34655.001
Introduction
Antiretroviral therapy (ART) has transformed HIV infection from a uniformly deadly disease into a
chronic lifelong condition, saving millions of lives. However, ART interruption leads to rapid viral
rebound within weeks due to the persistence of proviral latency in rare, long-lived resting CD4+ T
cells and possibly in tissue macrophages (Honeycutt et al., 2017). HIV latency is defined as the pres-
ence of a transcriptionally silent but replication-competent proviral genome. Latency allows infected
cells to evade both immune clearance mechanisms and currently available ART, which is based solely
on the elimination of actively replicating virus.
An extensively investigated approach to purging latent HIV is the ‘shock and kill’ strategy, which
consists of forcing the reactivation of latent proviruses (‘shock’ phase) with the use of latency revers-
ing agents (LRAs), while maintaining ART to prevent de novo infections. Subsequently, reactivation
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of HIV expression would expose such cells (shocked cells) to killing by viral cytopathic effects and
immune clearance (‘kill’ phase). A variety of LRAs have been explored in vitro and ex vivo, with only
a few candidates being advanced to testing in pilot human clinical trials. Use of histone deacetylase
inhibitors (HDACi: vorinostat, panobinostat, romidepsin, and disulfiram) in clinical studies has shown
increases in cell-associated HIV RNA production and/or plasma viremia after in vivo administration
(Archin et al., 2012a; Elliott et al., 2015; Elliott et al., 2014; Rasmussen et al., 2014;
Søgaard et al., 2015). However, none of these interventions alone has succeeded in significantly
reducing the size of the latent HIV reservoir (Rasmussen and Lewin, 2016).
Several obstacles can explain the failure of LRAs, as reviewed in (Margolis et al., 2016;
Rasmussen et al., 2016). However, the biggest challenge to date is our inability to accurately quan-
tify the size of the reservoir. The absolute quantification (number of cells) of the latent reservoir in
vivo (and ex vivo) has thus far been technically impossible. The most sensitive, quickest, and easiest
assays to measure the prevalence of HIV-infected cells are PCR-based, quantifying total or inte-
grated HIV DNA or RNA transcripts. However these assays substantially overestimate the number of
latently infected cells, due to the predominance of defective HIV DNA genomes in vivo
(Bruner et al., 2016; Ho et al., 2013). The best currently available assay to measure the latent reser-
voir is the relatively cumbersome viral outgrowth assay (VOA), which is based on quantification of
the number of resting CD4+ T cells that produce infectious virus after a single round of maximum in
vitro T-cell activation. After several weeks of culture, viral outgrowth is assessed by an ELISA assay
for HIV-1 p24 antigen or a PCR assay for HIV-1 RNA in the culture supernatant. Importantly, the
number of latently infected cells detected in the VOA is 300-fold lower than the number of resting
CD4+ T cells that harbor proviruses detectable by PCR.
This reliance on a single round of T-cell activation likely incorrectly estimates the viral reservoir for
two reasons. First, the discovery of intact non-induced proviruses indicates that the size of the latent
reservoir may be much greater than previously thought: the authors estimate that the number may
be at least 60 fold higher than estimates based on VOA (Ho et al., 2013; Sanyal et al., 2017). This
work and that of others (Chen et al., 2017) highlight the heterogeneous nature of HIV latency and
suggest that HIV reactivation is a stochastic process that only reactivates a small fraction of latent
viruses at any given time (Dar et al., 2012; Ho et al., 2013; Singh et al., 2010; Weinberger et al.,
2005). Second, the ability of defective proviruses to be transcribed and translated in vivo
(Pollack et al., 2017): this study shows that, although defective proviruses cannot produce infectious
particles, they express viral RNA and proteins, which can be detectable by any p24 antigen or PCR
assays used for the reservoir-size quantification.
Thus, current assays underestimate the actual number of latently infected cells, both in vivo and
ex vivo, and the real size of HIV reservoir is still to be determined. Therefore, it has been difficult to
judge the potential of LRAs in in vitro (latency primary models), ex-vivo (patients’ samples) and in
vivo (clinical trial) experiments.
HIV latency is a complex, multi-factorial process (reviewed in [Dahabieh et al., 2015]). Its estab-
lishment and maintenance depend on: (a) viral factors, such as integrase that specifically interacts
with cellular proteins, including LEDGF, (b) trans-acting factors (e.g., transcription factors) and their
regulation by the activation state of T cells and the environmental cues that these cells receive, and
(c) cis-acting mechanisms, such as the local chromatin environment at the site of integration of the
virus into the genome. Recent evidence has also highlighted the association of specific HIV-1 inte-
gration sites with clonal expansion of latently infected cells (reviewed in [Maldarelli, 2016]).
The role of the site of HIV integration into the cellular genome in the establishment and mainte-
nance of HIV latency has remained controversial. While early studies found that the HIV integration
site does affect both the entry into latency (Chen et al., 2017; Jordan et al., 2003; Jordan et al.,
2001), and the viral response to LRAs (Chen et al., 2017), other studies have failed to find a signifi-
cant role of integration sites in regulating the fate of HIV infection (Dahabieh et al., 2014; Sherrill-
Mix et al., 2013).
In this study, we have used a new dual color reporter virus, HIVGKO, to investigate the reactivation
potential of various LRAs in pure latent population. We find that latency is heterogeneous and that
only a small fraction (<5%) of the latently infected cells is reactivated by LRAs. We also show that
both genomic localization and chromatin context of the integration site affect the fate of HIV infec-
tion and the reversal of viral latency.
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Results
A second-generation dual-fluorescence HIV-1 reporter (HIVGKO) to
study latency
Our laboratory reported the development of a dual-labeled virus (DuoFluoI) in which eGFP is under
the control of the HIV-1 promoter in the 50 LTR and mCherry is under the control of the cellular elon-
gation factor one alpha promoter (EF1a) (Calvanese et al., 2013). However, we noted that the
model was limited by a modest number of latently infected cells (<1%) generated regardless of viral
input (Figure 1—figure supplement 1A–1C), as well as a high proportion of productively infected
cells in which the constitutive promoter EF1a was not active (GFP+, mCherry-).
To address these issues, which we suspected were due to recombination between the 20–30 bp
regions of homology at the N- and C-termini of the adjacent fluorescent proteins (eGFP and
mCherry) (Salamango et al., 2013), we generated a new version of dual-labeled virus (HIVGKO), con-
taining a codon-switched eGFP (csGFP) and a distinct, unrelated fluorescent protein mKO2 under
the control of EF1a (Figure 1A). First, titration of HIVGKO input revealed that productively and
latently infected cells increased proportionately as the input virus increased (Figure 1B and Figure
1—figure supplement 1), unlike the original DuoFluoI (Figure 1—figure supplement 1). Second,
comparison of primary CD4+ T cells infected with HIVGKO or the original DuoFluoI revealed an
increase in double-positive (csGFP+ mKO2+) infected cells in HIVGKO infected cells (Figure 1C). A
small proportion of csGFP+ mKO2- cells were still visible in HIVGKO infected cells. We generated a
HIVGKO virus lacking the U3 promoter region of the 3
0LTR (DU3-GKO), resulting in an integrated virus
devoid of the 5’ HIV U3 region. This was associated with a suppression of HIV transcription and an
inversion of the latency ratio (ratios latent/productive = 0.34 for HIVGKO-WT-LTR and 8.8 for HIVGKO-D
U3-3’LTR - Figure 1D). Finally, to further characterize the constituent populations of infected cells,
double-negative cells, latently and productively infected cells were sorted using FACS and analyzed
for viral mRNA and protein content. (Figures 1E and F, Figure 1—source data 1). As expected,
productively infected cells (csGFP+) expressed higher amounts of viral mRNA and viral proteins, but
latently infected cells (csGFP- mKO2+) had very small amounts of viral mRNA and no detectable viral
proteins.
Based on all these findings, the second-generation of dual-fluorescence reporter, HIVGKO, is able
to more accurately quantify latent infections in primary CD4+ T cells than HIVDuoFluoI, and thus allows
for the identification and purification of a larger number of latently infected cells. Using flow cytome-
try, we can determine infection and HIV productivity of individual cells and simultaneously control
for cell viability.
Correlation between LRA efficacy in HIV-infected patient samples and
activity in HIVGKO latently infected cells
Next, we evaluated the reactivation of latent HIVGKO in primary CD4
+ T cells by LRAs, and compared
it with the ability of the same LRAs to reverse latency in CD4+ T cells isolated from HIV-infected indi-
viduals. We tested the following LRAs: (a) the histone deacetylase inhibitor (HDACi) panobinostat
(Rasmussen et al., 2013), (b) the bromodomain-containing protein 4 (BRD4) inhibitor JQ1, which
acts through positive transcription elongation factor (P-TEFb) (Banerjee et al., 2012; Boehm et al.,
2013; Filippakopoulos et al., 2010; Li et al., 2013; Zhu et al., 2012), and (c) the PKC activator,
bryostatin-1 (del Real et al., 2004; Mehla et al., 2010). Viral reactivation mediated by these LRAs
was compared to treatment of CD4+ T cells with aCD3/CD28 (Spina et al., 2013). Several studies
have shown synergetic effects when combining different LRAs (Darcis et al., 2015; Jiang et al.,
2015; Laird et al., 2015; Martı´nez-Bonet et al., 2015), therefore we also tested bryostatin-1 in
combination with either panobinostat or JQ1. Drugs were used at concentrations previously shown
to be effective at reversing latency in other model systems (Archin et al., 2012a; Bullen et al.,
2014; Laird et al., 2015; Spina et al., 2013).
To measure reactivation by LRAs in patient samples, we treated 5 million purified resting CD4+ T
cells from four HIV infected individuals on suppressive ART (participant characteristics in Table 1)
with single LRAs, combinations thereof, or vehicle alone for 24 hr. LRAs efficacy was assessed using
a PCR-based assay, by measuring levels of intracellular HIV-1 RNA using primers and a probe that
detect the 30 sequence common to all correctly terminated HIV-1 mRNAs (Bullen et al., 2014). Of
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Figure 1. Second generation of dual-fluorescence HIV-1 reporter, HIVGKO to quantify stable latency. (A) Schematic representation of first (top:
HIVDuoFluoI) and second generation (bottom: HIVGKO) of dual-labeled HIV-1 reporters. (B) Representative experiment of HIVGKO virus titration in
activated primary CD4+ T cells (4 days post-infection). Primary CD4+ T cells were activated with aCD3/CD28 beads + 20 U/mL IL-2 for 3 days before
infection with different amounts of HIVGKO (input, ng/p24) and analyzed by flow cytometry 4 days post-infection. (C) Comparison of HIVDuoFluoI and
Figure 1 continued on next page
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the LRAs tested individually, none exhibited a statistically significant effect (n=4 - Figure 2A, Fig-
ure 2—source data 1). Importantly, T-cell activation positive control, aCD3/CD28 (24.4-fold,
Figure 2A), showed expected fold induction value (10 to 100-fold increases of HIV RNA in PBMCs
[Bullen et al., 2014; Darcis et al., 2015; Laird et al., 2015]). Combinations of the PKC agonist
bryostatin-1 with JQ1 or with panobinostat (fold-increases of 126.2- and 320.8-fold, respectively,
Figure 2A), were highly more effective than bryostatin-1, JQ1 or panobinostat alone (fold-increases
of 6.8, 1.7- and 2.9-fold, respectively, Figure 3A), and even greater than T-cell activation with
aCD3/CD28. This observation is consistent with previous reports (Darcis et al., 2015; Jiang et al.,
2015; Laird et al., 2015; Martı´nez-Bonet et al., 2015).
The same LRAs and combinations were next tested after infection of human CD4+T cells in vitro
with HIVGKO. Measurement of intracellular HIV-1 mRNA in HIVGKO latently infected cells showed an
expected fold induction of latency in response to aCD3/CD28 (11.3-fold, Figure 2B, Figure 2—
source data 1). Second, JQ1, panobinostat, and bryostatin-1 alone all caused limited reactivation of
latent HIV (fold-increases of 1.1-, 5.6- and 6.2-fold, respectively, Figure 2B), as observed in patients’
samples. Finally, we observed low synergy when combining bryostatin and JQ1 (8-fold increase), but
high synergy between bryostatin and panobinostat (67.3-fold increase). These data together demon-
strate that HIVGKO closely mimics in vitro what is observed in ex vivo patients’ samples (correlation
rate r2 = 0.88, p=0.0056 - Figure 2C), and validate the robustness and reliability of the dual-flores-
cence HIV reporter as a model to study HIV-1 latency.
HIV-1 LRAs target a minority of latently infected primary CD4+ T cells
Current assays have relied on PCR-based assays to measure HIV RNA, and to evaluate the efficacy of
different LRAs (Figure 2A). The use of dual-fluorescent HIV reporters, however, provides a tool to
quantify directly the fraction of cells that become reactivated.
To quantify the absolute number of latently infected cells reactivated following LRA treatment,
primary CD4+ T cells were infected with HIVGKO, and cultured for 5 days (in the presence of IL-2)
before sorting the pure latent population (GFP-, mKO2+). Cells were allowed to rest overnight and
Figure 1 continued
HIVGKO infection profiles by flow cytometry in activated primary CD4
+ T-cells (4 days post-infection). Cells were treated as in (B). (D) Comparison of
GKO-WT-LTR and GKO-DU3 3’LTR infection profiles by flow cytometry in cells treated as in (B). (E, F) Primary CD4+ T cells were treated as in (B). At 4
days post-infection, double-negative, productively infected, and latently infected cells were sorted out, and (E) the total RNA isolated from each
population was subjected to Taqman RT-qPCR analysis (Source Data - Figure 1). Unspliced (US), singly spliced (SS), and multiply spliced (MS) HIV-1
mRNAs were quantified relative to cellular GAPDH. (F) Western blot analysis of each population.
DOI: https://doi.org/10.7554/eLife.34655.002
The following source data and figure supplement are available for figure 1:
Source data 1. Taqman RT-qPCR analysis of unspliced (US), singly spliced (SS), and multiply spliced (MS) HIV-1 mRNAs in the uninfected, double nega-
tive, latent and productive populations.
DOI: https://doi.org/10.7554/eLife.34655.004
Figure supplement 1. Comparison of HIVGKO and HIVDuoFluoI.
DOI: https://doi.org/10.7554/eLife.34655.003
Table 1. Characteristics of HIV-1-infected study participants
ABC, abacavir; DRV, darunavir; FTC, emtricitabine; RPV, rilpivirine; RTV, ritonavir; TCV, tivicay; TDF, tenofovir; 3TC, lamivudine; VL, viral
load.
Scope
ID Age Sex Ethnicity
CD4
Count
Duration of infection
(years) ART regimen
Duration of ART
(years)
Peak reporter VL (copies/
ml 1)
1597 56 M Mixed 469 19 RPV/TDF/FTC 5 45734
2147 59 M Asian 597 28 RPV/TDF/FTC 23 374000
2461 62 M White 664 32 RPV/TCV 19 20000
3162 54 M White 734 29 RTV, DRV, ABC/TCV/
3TC
20 171000
DOI: https://doi.org/10.7554/eLife.34655.009
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were treated for 24 hr with the various LRAs (same drug concentrations as in Figure 2) (Figure 3A,
Figure 3—source data 1). Culture of DMSO-treated latently infected primary CD4+ T cells produced
little spontaneous reactivation (average of four experiments: 1.4% of GFP+ cells). Unexpectedly, we
found that none of the individual LRAs or their combinations reactivated more than 5.5% of the
latently infected cells: JQ1 (1.7%) panobinostat (3.7%), bryostatin-1 (3%) aCD3/CD28 (4.5%), bryos-
tatin-1 and JQ1 (3.3%.). bryostatin-1 and panobinostat (5.5%) (Figure 3B).
Small fractional rate of latency reactivation is not explained by low
cellular response to activation signals
These data highlight two important facts: a) cell-associated HIV RNA quantification does not reflect
the absolute number of cells undergoing viral reactivation, and b) induced cell-associated HIV RNA,
in response to all reversing agents, comes from a small fraction of reactivated latent cells. This was
particularly surprising with aCD3/CD28 stimulation, as a currently accepted model for HIV latency is
that the state of T cell activation dictates the transcriptional state of the provirus. Treatment of
latently infected primary CD4+ T cells with aCD3/CD28 stimulated HIV production in less than 5% of
the cells, while the other 95% remained latent, even though after 24 hr of treatment nearly all of the
cells had upregulated the early T cell activation marker CD69 (Figure 4—figure supplement 1).
To further rule out the possibility that non-reactivated latently infected cells (NRLIC) simply repre-
sented a lack of efficient response to T-cell activation signals, we analyzed T-cell activation markers
within the different populations (i.e., within uninfected, non reactivated (NRLIC) and reactivated
latently infected cells (RLIC); Figure 4, Figure 4—source data 1). Briefly, 72h-stimulated CD4+ T
cells were infected with HIVGKO, and 4 days later, GFP- cells were sorted, and allowed to rest
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Figure 2. LRAs efficacy in patient samples is predicted by activity in HIVGKO latently infected cells. (A) Intracellular HIV-1 mRNA levels in rCD4s,
obtained from infected individuals and treated ex vivo with a single LRA or a combination of two LRAs for 24 hr in presence of raltegravir, presented as
fold induction relative to DMSO control. (n = 4, mean +SEM) (Figure 2—source data 1). (B) Intracellular HIV-1 mRNA levels in HIVGKO latently infected
CD4+ T-cells, and treated with a single LRA or a combination of two LRAs for 6 hr in presence of raltegravir, presented as fold induction relative to
DMSO control. (n = 3 (different donors), mean +SEM, paired t-test) (Figure 2—source data 1). (C) Correlation between intracellular HIV-1 mRNA levels
quantified in either 6 hr stimulated HIVGKO latently infected CD4
+ T-cells from different donors, or 24 hr stimulated rCD4s from HIV infected patients,
with a single LRA or a combination of two LRAs in presence of raltegravir.
DOI: https://doi.org/10.7554/eLife.34655.005
The following source data is available for figure 2:
Source data 1. Intracellular HIV-1 mRNA levels in rCD4s, obtained from infected individuals, or in HIVGKO latently infected CD4
+ T-cells.
DOI: https://doi.org/10.7554/eLife.34655.006
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Figure 3. Few HIVGKO latently infected primary CD4
+ T cells are reactivated. (A) Schematic of experimental
procedure with primary CD4+ T cells. Briefly, CD4+ T cells were purified from blood of healthy donors and
activated for 72 hr with aCD3/CD28 beads and 100 U/ml IL-2 before infection with HIVGKO. Five days post-
infection, latently infected cells (csGFP- mKO2+) cells were sorted, put back in culture overnight and stimulated
with different LRAs in presence of raltegravir for 24 hr before performing FACS analysis. (B) Percentage of GFP
+ cells is shown after stimulation of latently infected CD4+ T-cells with LRAs (n = 4 (different donors), mean +SEM,
paired t-test) (Figure 3—source data 1). (C) Histogram plot of percent live cells for each drug treatment (n = 3
(different donors), mean + SEM, paired t-test) (Figure 3—source data 1). p-value: *p<0.05, **p<0.01 relative to
DMSO.
DOI: https://doi.org/10.7554/eLife.34655.007
Figure 3 continued on next page
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overnight before restimulation with aCD3/CD28. After another 24 hr, cells were stained for the
early, intermediate, and late markers of T cell activation CD69, CD25 and HLA-DR respectively. The
three different populations, double negative, RLIC and NRLIC, had similar profiles of activated T-cell
subsets, as shown in Figure 4, and were mainly composed of strongly activated cells (CD69+/CD25
Figure 3 continued
The following source data is available for figure 3:
Source data 1. Percentage of GFP+ cells is shown after stimulation of latently infected CD4+ T-cells with LRAs as
well as percent live cells for each drug treatment.
DOI: https://doi.org/10.7554/eLife.34655.008
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Figure 4. Low-level latency reactivation is not explained by low cellular responses to activation signals. T-cell
activation patterns between double negative, reactivated (RLIC) and non-reactivated (NRLIC) latently infected cells.
Briefly, CD4+ T-cells were purified from blood of four healthy donors and activated for 72 hr with aCD3/CD28
beads and 20 U/ml IL-2 before infection with HIVGKO. At 4 days post-infection, csGFP- were sorted, cultured
overnight and stimulated with aCD3/CD28 in presence of raltegravir. At 24 hr post-treatment, cells were stained
for CD25, CD69, and HLA-DR activation markers before performing FACS analysis. (n = 4, mean +SEM, paired
t-test; *p<0.05; **p<0.01) (Figure 4—source data 1).
DOI: https://doi.org/10.7554/eLife.34655.010
The following source data and figure supplement are available for figure 4:
Source data 1. CD25, CD69, and HLA-DR activation markers patterns between double negative, reactivated (RLIC)
and non-reactivated (NRLIC) latently infected cells.
DOI: https://doi.org/10.7554/eLife.34655.012
Figure supplement 1. 24 hr treatment effectively activate primary CD4+ T cells.
DOI: https://doi.org/10.7554/eLife.34655.011
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+/HLA-DR+/-). We only observed a statistically significant increase of NRLIC compared with RLIC in
the CD69+/CD25-/HLA-DR+ population, however this small increase in a relatively minor population
is insufficient to explain the low reactivation rate of latently infected cells. Overall, comparison of
both reactivated and non reactivated latent populations showed little difference in their activation
state.
Integration sites, gene expression, transcription units and the fate of
HIV infection
The role of the site of HIV integration into the genome in latency remains a subject of debate
(Chen et al., 2017; Dahabieh et al., 2014; Jordan et al., 2003; Jordan et al., 2001; Sherrill-
Mix et al., 2013). To identify possible differences in integration sites between reactivated and non-
reactivated HIV genomes, primary CD4+ T-cells were infected with HIVGKO. At 5 days post-infection,
productively infected cells (GFP+, PIC) were sorted and frozen. The GFP negative population (con-
sisting of a mixture of latent and uninfected) was isolated and treated with aCD3/CD28. 48 hr post-
induction, both non reactivated (NRLIC) and reactivated (RLIC) populations were isolated. Nine
libraries (three donors, three samples/donor: PIC, RLIC, NRLIC) were constructed from genomic
DNA as described (Cohn et al., 2015) and analyzed by high-throughput sequencing to locate HIV
proviruses within the human genome. A total of 1803 virus integration sites were determined: 960
integrations in PIC, 681 in NRLIC, and 162 in RLIC (Integration Sites Source data).
To determine whether integration within genes differentially expressed during T-cell activation
predicted infection reactivation fate, we compared our HIV integration dataset with a published
dataset for gene expression in resting and activated (48 hr - aCD3/CD28) CD4+ T cells from healthy
individuals (Ye et al., 2014). The analysis revealed that most of the aCD3/CD28-induced latent pro-
viruses were not integrated in genes responsive to T-cell activation signals (Figure 5A and B, Fig-
ure 5—source data 1). Interestingly, PIC and RLIC integration events were associated with genes
whose basal expression was significantly higher than genes targeted in NRLIC, both in activated and
resting T cells (Figure 5C, Figure 5—source data 2).
Next, we investigated whether different genomic regions were associated with productive, induc-
ible or non-inducible latent HIV-1 infections. In agreement with previous studies (Cohn et al., 2015;
Dahabieh et al., 2014; Maldarelli et al., 2014; Wagner et al., 2014), the majority of integration
sites were found within genes in each population (Figure 6A, Figure 6—source data 1), although
the proportion of genic integrations in NRLIC was significantly lower than in PIC and RLIC samples.
Moreover, integration events in the PIC and RLIC populations were more frequent in transcribed
regions (64% and 58%, respectively, [sum of low + medium + high transcribed regions] (Figure 6B),
Figure 6—source data 1), while these regions were significantly less represented in the NRLIC
(31%) (Figure 6B). As expected since introns represent a much larger proportion of genes, genic
integration events were more frequent in the introns for each population (>65%, Figure 6C, Fig-
ure 6—source data 1). Finally, viral orientation of proviruses with respect to the transcriptional unit
did not correlate with the fate of HIV infection (latent vs productive) or the reactivation or absence
thereof of HIV latency (Figure 6D, Figure 6—source data 1).
Chromatin modifications at the site of HIV integration and latency
Chromatin marks, such as histone post-translational modifications (e.g., methylation and acetylation)
and DNA methylation, are involved in establishing and maintaining HIV-1 latency (De Crignis and
Mahmoudi, 2017). We examined 500 bp regions centered on all integration sites in each population
for several chromatin marks by comparing our data with several histone modifications and DNaseI
ENCODE datasets. We first looked at distinct and predictive chromatin signatures, such as
H3K4me1 (active enhancers), H3K36m3 (active transcribed regions), H3K9m3 and H3K27m3 (repres-
sive marks of transcription) (reviewed in [Kumar et al., 2015; Shlyueva et al., 2014]). All three popu-
lations exhibited distinct profiles, although productive and inducible latent infections profiles
appeared most similar (Figure 7A, Figure 7—source data 1). The analysis showed that PIC integra-
tion events were associated with active chromatin (i.e., transcribed genes - H3K36me3 or enhancers
- H3K4me1), while NRLIC integration events appeared biased toward heterochromatin (H3K27me3
and H3K9me3) and non-accessible regions (DNase hyposensitivity).
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Marini et al. recently reported that HIV-1 mainly integrates at the nuclear periphery (Marini et al.,
2015). We therefore examined the topological distribution of integration sites from each population
inside the nucleus by comparing our integration site data with a previously published dataset of
lamin-associated domains (LADs) (Guelen et al., 2008). LADs consist of H3K9me2 heterochromatin
and are present at the nuclear periphery. This analysis showed that latent integration sites from both
RLIC and NRLIC were in LADs to a significantly higher degree (32% and 30.4%) than productive inte-
grations (23.6%) (p<0.05, Figure 7B, Figure 7—source data 1). Overall, these data show similar fea-
tures between productively infected cells and inducible latently infected cells, while non-reactivated
latently infected cells appear distinct from the other populations. These findings support a promi-
nent role for the site of integration and the chromatin context for the fate of the infection itself, as
well as for latency reversal.
Discussion
Dual-color HIV-1 reporters are unique and powerful tools (Calvanese et al., 2013; Dahabieh et al.,
2013), that allow for the identification and the isolation of latently infected cells from productively
infected cells and uninfected cells. Latency is established very early in the course of HIV-1 infection
(Archin et al., 2012b; Chun et al., 1998; Whitney et al., 2014) and, until the advent of dual-
reporter constructs, no primary HIV-1 latency models have allowed the study of latency heterogene-
ity at this very early stage. Importantly, the comparison of data obtained from distinct primary HIV-1
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Figure 5. Relative expression of HIV-1 integration targeted genes for each population, before or after TCR activation. (A) Scatter chart showing primary
CD4+ T-cell gene expression changes after 48 hr of stimulation with aCD3/CD28 beads. Integration sites displayed outside of the two solid gray lines
were targeted genes whose expression is at least ± twofold differentially expressed after 48 hr stimulation. Plot points size can be different, the bigger
the plot point is, the more integration events happened within the same gene. (B) Fraction of integration sites from the different populations PIC, RLIC
or NRLIC, integrated within genes whose expression is at least ± twofold differentially expressed after 48 hr of aCD3/CD28 stimulation (**p<0.01;
***p<0.001; two-proportion z test) (Figure 5—source data 1). (C) Relative expression of genes targeted by HIV-1 integration in PIC, RLIC or NRLIC
before TCR stimulation and after aCD3/CD28 stimulation (n = 3, mean +SEM, paired t-test). ***p<0.001; ****p<0.0001. (Figure 5—source data 2).
DOI: https://doi.org/10.7554/eLife.34655.013
The following source data is available for figure 5:
Source data 1. Fraction of integration sites from the different populations PIC, RLIC or NRLIC, integrated within genes whose expression is at
least ± twofold differentially expressed after 48 hr of aCD3/CD28 stimulation.
DOI: https://doi.org/10.7554/eLife.34655.014
Source data 2. Relative expression of genes targeted by HIV-1 integration in PIC, RLIC or NRLIC before TCR stimulation and after 48 hr aCD3/CD28
stimulation.
DOI: https://doi.org/10.7554/eLife.34655.015
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latency models is complicated as some models are better suited to detect latency establishment (e.
g., dual-reporters), while others are biased towards latency maintenance (e.g., Bcl2-transduced
CD4+ T cells). The use of env-defective viruses limits HIV replication to a single-round and, thereby
limits the appearance of defective viruses (Bruner et al., 2016).
In this study, we describe and validate an improved version of HIVDuoFluoI, previously developed
in our laboratory (Calvanese et al., 2013), which accurately allows for: (a) the quantification of
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Figure 6. Insertion landscapes of HIV-1. (A) Proportion of mapped insertions that are in genic or intergenic regions. (Figure 6—source data 1). (B)
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***p<0.001; ****p<0.0001 using two-proportion z test.
DOI: https://doi.org/10.7554/eLife.34655.016
The following source data is available for figure 6:
Source data 1. Proportion of mapped insertions that are in genic or intergenic regions; of integration sites in transcribed regions with high, medium,
low expression, trace or silent expression; of unique genic integration sites located in introns, exons, UTR or promoters; and transcriptional orientation
of integrated HIV-1 relative to host gene.
DOI: https://doi.org/10.7554/eLife.34655.017
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latently infected cells, (b) the purification of latently infected cells, and (c) the evaluation of the
‘shock and kill’ strategy. Our data highlight two important facts: (a) cell-associated HIV RNA quantifi-
cation does not reflect the number of cells undergoing viral reactivation, and (b) a small portion of
the cells carrying latent proviruses (<5%) is reactivated, although LRAs target the whole latent popu-
lation. Hence, even if cells harboring reactivated virus die, this small reduction would likely remain
undetectable when quantifying the latent reservoir in vivo. Our data are in agreement with previous
reports, which show that levels of cellular HIV RNA and virion production are not correlated, and
that the absolute number of cells being reactivated by aCD3/CD28 is indeed limited to a small frac-
tion of latently infected cells (Cillo et al., 2014; Sanyal et al., 2017; Yucha et al., 2017). Using our
dual-fluorescence reporter, we confirm these findings, and extend these observations to LRAs com-
binations. However, although LRAs combinations show synergy when measuring cell-associated HIV
RNA, we do not find such synergy at the level of individual cells, but rather only partial additive
effect. Our work, as well as that of others (Cillo et al., 2014; Sanyal et al., 2017; Yucha et al.,
2017), demonstrate the importance of single cell analysis when it comes to the evaluation of poten-
tial LRAs. Indeed, it is necessary to determine wheter potential increases in HIV RNA after stimula-
tion in a bulk population result from a small number of highly productive cells, or from a larger but
less productive population, as these two mechanisms likely have very different impacts on the latent
reservoir.
Our data further highlight the heterogeneous nature of the latent reservoir (Chen et al., 2017;
Ho et al., 2013). We currently have a limited understanding of why some latently infected cells are
capable of being induced while others are not. It is possible that different chromatin environments
impose different degrees of transcriptional repression on the integrated HIV genome, with the non
reactivatable latent HIV corresponding to the most repressive environment. (Chen et al., 2017).
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Figure 7. Epigenetics marks and nuclear localization of HIV-1 integration sites. (A) 500 bp centered on HIV-1 integration sites for each population were
analyzed for the presence of H3K4me1 (active enhancers), H3K36m3 (active transcribed regions), H3K9m3 and H3K27m3 (repressive marks of
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DOI: https://doi.org/10.7554/eLife.34655.018
The following source data is available for figure 7:
Source data 1. HIV-1 integration sites for each population were analyzed for the presence of H3K4me1, H3K36m3, H3K9m3, H3K27m3, DNA accessibil-
ity, as well as their nuclear localization.
DOI: https://doi.org/10.7554/eLife.34655.019
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Since HIVGKO allows for the isolation of productively infected cells and reactivated latent cells from
those that do not reactivate, it provides a unique opportunity to explore the impact of HIV integra-
tion on the fate of the infection.
Different integration site-specific features contribute to latency, such as the chromatin structure,
including adjacent loci but also the provirus location in the nucleus (Lusic and Giacca, 2015;
Lusic et al., 2013). Viral integration is a semi-random process (Bushman et al., 2005) in which HIV-1
preferentially integrates into active genes (Barr et al., 2006; Bushman et al., 2005;
Demeulemeester et al., 2015; Ferris et al., 2010; Han et al., 2004; Lewinski et al., 2006;
Mitchell et al., 2004; Schro¨der et al., 2002; Sowd et al., 2016; Wang et al., 2007). LEDGF, one of
the main chromatin-tethering factors of HIV-1, binds to the viral integrase and to H3K36me3, and to
a lesser extent to H3K4me1, thus directing the integration of HIV-1 into transcriptional units
(Daugaard et al., 2012; Eidahl et al., 2013; Pradeepa et al., 2012). Also CPSF6, which binds to the
viral capsid, markedly influences integration into transcriptionally active genes and regions of
euchromatin (Sowd et al., 2016), explaining how HIV-1 maintains its integration in the euchromatin
regions of the genome independently of LEDGF (Quercioli et al., 2016). Several studies have char-
acterized the integration sites, however, these analyses have been restricted to productive
infections.
Using ENCODE reference datasets, our data are consistent with previous results, showing that
HIV-1 preferentially targets actively transcribed regions (Marini et al., 2015; Wang et al., 2007;
Chen et al., 2017). However, non-inducible latent proviruses are observed to be integrated to a
higher extent into silenced chromatin. In addition, even though HIV integration is normally strongly
disfavored in the heterochromatic condensed regions in LADs due to low chromatin accessibility, we
show that some HIV integration does occur in LADs when using a previously published dataset of
LADs (Guelen et al., 2008; Marini et al., 2015), and that latent proviruses that are not readily reacti-
vatable are integrated at higher extent in LADs.
Importantly, we identify a unique rare population among the latent cells that can be reactivated.
In contrast to the non-inducible latent infections, the latency reversal of inducible latent proviruses
might be explained by integration in an open chromatin context, similar to integration sites for pro-
ductive proviruses, followed by subsequent heterochromatin formation and proviral silencing. As a
consequence, the distinct integration sites between induced and non-induced latent proviruses high-
light new possibilities for cure strategies. Indeed, the ‘shock and kill’ strategy aims to reactivate and
eliminate every single replication-competent latent provirus, since a single remaining cell carrying a
latent inducible provirus could, in theory, reseed the infection. However, our study and others point
out several significant barriers to successful implementation of the ‘shock and kill’ strategy. First,
LRAs only reactivate a limited fraction of latent proviruses. It is likely that some of the non-induced
proviruses, such as those integrated into enhancers and transcriptionnal active regions of the
genome, will reactivate after several rounds of activation, due to the stochastic nature of HIV activa-
tion (Dar et al., 2012; Ho et al., 2013; Singh et al., 2010; Weinberger et al., 2005). It is also likely
that better suited LRAs combinations (two or more LRAs) will reactivate some of the non-induced
proviruses integrated into silenced chromatin marked by H3K27me3 and H3K9me3. Indeed, several
studies have shown that the pharmaceutical inhibition of H3K27me3 and H3K9me2/3 could sensitize
latent proviruses to LRAs (Friedman et al., 2011; Nguyen et al., 2017; Tripathy et al., 2015). Sec-
ond, Shan et al. have shown that latently reactivated cells are not cleared due to cytopathic effects
or CTL response implying that immunomodulatory approaches, in addition of more potent LRAs, are
likely required to achieve a cure for HIV infection (Shan et al., 2012).
In conclusion, the heterogeneity of the latent reservoir calls for therapies addressing the different
pools of latently infected cells. While ‘shock and kill’ might be helpful in reactivating and possibly
eliminating a small subset of highly reactivatable latent HIV genomes, other approaches will be nec-
essary to control or eliminate the less readily reactivatable population identified here and in patients.
Perhaps, this latter population should rather be ‘blocked and locked’ using latency-promoting
agents (LPAs), as described by several groups (Besnard et al., 2016; Kessing et al., 2017;
Kim et al., 2016; Vranckx et al., 2016). For a functional cure, a stably silenced, non-reactivatable
provirus is preferable to a lifetime of chronic active infection.
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Materials and methods
Patients’ samples
Four HIV-1-infected individuals, who met the criteria of suppressive ART, undetectable plasma HIV-1
RNA levels (<50 copies/ml) for a minimum of six months, and with CD4+ T cell count of at least 350
cells/mm3, were enrolled. The participants were recruited from the SCOPE cohort at the University
of California, San Francisco. Table 1 details the characteristics of the study participants.
Plasmids construction
To construct HIVGKO, the csGFP sequence was designed and ordered from Life Technologies. The
sequence was cut out from Life Technologies’ plasmid with BamHI and XhoI and cloned into Duo-
FluoI, previously cut with the same enzymes (DuoFluoI-csGFP). HIVGKO was creating by PCR overlap-
ping: csGFP-EF1a (Product 1) was PCR amplified from DuoFluoI using primers P1: 5’ for-GATTAG
TGAACGGATCCTTGGCAC-3’ and P2: 5’ rev-GGCTTGATCACAGAAACCATGGTGGCGACCGG
TAGCGC-3’. mKO2 (Product 2) was PCR amplified from Brian Webster’s plasmid (kind gift from
Warner Greene) using primers P3: 5’ for-GCGCTACCGGTCGCCACCATGGTTTCTGTGATCAA
GCC-3’ and P4: 5’ rev-CTCCATGTTTTTCCAGGTCTCGAGCCTAGCTGTAGTGGGC CACGGC-3’.
Finally, we amplified the 3’LTR sequence (Product 3) from RGH plasmid (Dahabieh et al., 2013)
using primers P5: 5’ for-GCTCGAGACCTGGAAAAACATGGAG-3’ and P6: 5’ rev-GTGCCACC
TGACGTCTAAGAAACC-3’, to add a fragment containing the AatII restriction site, in order to ligate
the csGFP-EF1a-mKO2 cassette into pLAI (Peden et al., 1991). We then did sequential PCRs: prod-
ucts 1 and 2 were amplified using primers P1 and P4. PCR product (1 + 2) was mixed with product
three and PCR amplified with P1 and P6 thus creating the full cassette. The cassette csGFP-EF1a-
mKO2 was then digested with BamHI and AatII, and cloned into pLAI previously digested with the
same enzymes to create HIVGKO.
Of note, the Envelope open reading frame was disrupted by the introduction of a frame shift at
position 7136 by digestion with KpnI, blunting, and re-ligation.
To construct GKO-DU3 3’LTR, we cloned a DU3 linker from pTY-EFeGFP (Chang et al., 1999;
Cui et al., 1999; Iwakuma et al., 1999; Zolotukhin et al., 1996) into the KpnI/SacI sites of the 3’
LTR in HIVGKO.
Virus production
The production of HIVGKO and the assessment of HIV Latency Reversal Agents in Human Primary
CD4+ T Cells are described in more detail at Bio-protocol (Battivelli and Verdin, 2018). Pseudo-
typed HIVDuoFluoI and HIVGKO viral stocks were generated by co-transfecting (standard calcium phos-
phate transfection method) HEK293T cells with a plasmid encoding HIVDuoFluoI or HIVGKO, and a
plasmid encoding HIV-1 dual-tropic envelope (pSVIII-92HT593.1). Medium was changed 6–8 hr post-
transfection, and supernatants were collected after 48 hr, centrifuged (20 min, 2000 rpm, RT), fil-
tered through a 0.45 mM membrane to clear cell debris, and then concentrated by ultracentrifuga-
tion (22,000 g, 2 hr, 4˚C). Concentrated virions were resuspended in complete media and stored at
 80˚C. Virus concentration was estimated by p24 titration using the FLAQ assay (Gesner et al.,
2014).
Primary cell isolation and cell culture
CD4+ T cells were extracted from peripheral blood mononuclear cells (PBMCs) from continuous-flow
centrifugation leukophoresis product using density centrifugation on a Ficoll-Paque gradient (GE
Healthcare Life Sciences, Chicago, IL). Resting CD4+ lymphocytes were enriched by negative deple-
tion with an EasySepHuman CD4+ T Cell Isolation Kit (Stemcell Technologies, Canada). Cells were
cultured in RPMI medium supplemented with 10% fetal bovine serum, penicillin/streptomycin and 5
mM saquinavir.
Primary CD4+ T cells were purified from healthy donor blood (Blood Centers of the Pacific, San
Francisco, CA, and Stanford Blood Center), by negative selection using the RosetteSep Human
CD4+ T Cell Enrichment Cocktail (StemCell Technologies, Canada). Purified resting CD4+ T cells
from HIV-1 or healthy individuals were cultured in RPMI 1640 medium supplemented with 10% FBS,
L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 mg/ml), and IL-2 (20 to 100 U/ml) (37˚C,
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5% CO2). Spin-infected primary CD4
+ T cells were maintained in 50% of complete RPMI media sup-
plemented with IL-2 (20–100 U/ml) and 50% of supernatant from H80 cultures (previously filtered to
remove cells) without beads. Medium was replenished every 2 days until further experiment.
HEK293T cells were obtained from ATCC (mycoplasma free). Feeder cells H80 was a kind gift
from Jonathan Karn. H80 cells were cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), L-glutamine (2 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml) (37˚C, 5%
CO2). HEK293T cells were cultured in DMEM medium supplemented with 10% FBS, 50 U/ml penicil-
lin, and 50 mg/ml streptomycin.
Cell infection
Purified CD4+ T cells isolated from healthy peripheral blood were stimulated with aCD3/CD28 activ-
ating beads (Thermofisher, Waltham, MA) at a concentration of 0.5 bead/cell in the presence of 20–
100 U/ml IL-2 (PeproTech, Rocky Hill, NJ) for three days. All cells were spinoculated with either HIV-
DuoFluoI, HIVGKO or HIV D3U-GKO at a concentration of 300 ng of p24 per 1.10
6 cells for 2 hr at 2000
rpm at 32˚C without activation beads.
Infected cells were either analyzed by flow cytometry or sorted 4–5 days post-infection.
Latency-reversing agent treatment conditions
CD4+ T cells were stimulated for 24 hr unless stipulated differently, with latency-reversing agents at
the following concentrations for all single and combination treatments: 10 nM bryostatin-1, 1 mM
JQ1, 30 nM panobinostat, aCD3/CD28 activating beads (1 bead/cell), or media alone plus 0.1% (v/
v) DMSO. For all single and combination treatments, 30 mM Raltregravir (National AIDS Reagent Pro-
gram) was added to media. Concentrations were chosen based on Laird et al. paper (Laird et al.,
2015).
Staining, flow cytometry and cell sorting
Cells from Figure 4 were stained with a-CD69-PE-Cy7 (561928), a-CD25-APC (560987), and a-HLA-
DR-PerCP-Cy5.5 (562007) (BD Bioscience, Franklin Lakes, NJ).
Before collecting data using the FACS LSRII (BD Biosciences, Franklin Lakes, NJ) or the FACS
AriaII (BD Biosciences, Franklin Lakes, NJ, Figures 3 and 4), cells were stained with violet Live/Dead
Fixable Dead Cell Stain (Thermofisher, Waltham, MA) and fixed with 2% formaldehyde. Analyses
were performed with FlowJo V10.1 software (TreeStar).
Sorting of infected CD4+ T cells was performed with a FACS AriaII (BD Biosciences, Franklin
Lakes, NJ) based on their GFP and mKO2 fluorescence markers at 4/5 days post-infection, and
placed back in culture for further experimentation. In the experiments shown in Figures 2B and
4, we isolated both HIVGKO latently infected cells (GFP-, mKO2+, 3%) and uninfected cells (csGFP-,
mKO2-, 97%) five days post-infection, before treating cells with LRAs.
In the experiment shown in Figure 3, we isolated pure latent cells (GFP-, mKO2+) five days post-
infection, before treating this pure population with LRAs.
DNA, RNA and protein extraction, qPCR and western blot
RNA and proteins (Figure 1B and C) were extracted with PARISTM kit (Ambion, Thermofisher, Wal-
tham, MA) according to manufacturer’s protocol from same samples. RNA was retro-transcribed
using random primers with the SuperScript II Reverse Transcriptase (Thermofisher, Waltham, MA)
and qPCR was performed in the AB7900HT Fast Real-Time PCR System, using 2X HoTaq Real Time
PCR kit (McLab, South San Francisco, CA) and the appropriate primer-probe combinations described
in (Calvanese et al., 2013). Quantification for each qPCR reaction was assessed by the ddCt algo-
rithm, relative to Taq Man assay GAPDH Hs99999905_m1. Protein content was determined using
the Bradford assay (Bio-Rad, Hercules, CA) and 20 mg were separated by electrophoresis into 12%
SDS-PAGE gels. Bands were detected by chemiluminescence (ECL Hyperfilm Amersham, GE Health-
care Life Sciences, Chicago, I) with anti-Vif, HIV-p24 and a-actin (Sigma, Saint-Louis, MO) primary
antibodies.
Total RNA (Figure 2A and B) wasextracted using the Allprep DNA/RNA/miRNA Universal Kit
(Qiagen, Germany) with on-column DNAase treatment (Qiagen RNase-Free DNase Set, Germany).
cDNA synthesis was performed using SuperScript IV Reverse Transcriptase with a combination of
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random hexamers and oligo-dT primers (ThermoFisher, Waltham, MA). Relative cellular HIV mRNA
levels were quantified using a qPCR TaqMan assay using primers and probes described in
(Bullen et al., 2014) on a QuantStudio 6 Flex Real-Time PCR System (Thermofisher, Waltham, MA).
Relative cell-associated HIV mRNA copy numbers were determined in a reaction volume of 20 mL
with 10 mL of 2x TaqMan Universal Master Mix II with UNG ( Thermofisher, Waltham, MA), 4 pmol of
each primer, 4 pmol of probe, 0.5 mL reverse transcriptase, and 2.5 mL of cDNA. Cycling conditions
were 50˚C or 2 min, 95˚C for 10 min, then 60 cycles of 95˚C for 15 s and 60˚C for 1 min. Real-time
PCR was performed in triplicate reaction wells, and relative cell-associated HIV mRNA copy number
was normalized to cell equivalents using human genomic GAPDH expression by qPCR and applying
the comparative Ct method (Livak and Schmittgen, 2001).
HIV integration site libraries and computational analysis
HIV integration site libraries and computational analysis were executed in collaboration with Lilian B.
Cohn and Israel Tojal Da Silva as described in their published paper (Cohn et al., 2015), with a few
small changes added to the computational analysis pipeline. First, we included integration sites with
only a precise junction to the host genome. Second, to eliminate any possibility of PCR mispriming,
we have excluded integration sites identified within 100 bp (50 bp upstream and 50 bp downstream)
of a 9 bp motif identified in our LTR1 primer: TGCCTTGAG. Thirdly we have merged integration
sites within 250 bp and have counted each integration site as a unique event. The list of integration
sites for each donor and each population can be found as a source data file linked to this manuscript
(Integration Sites Source data 1).
Datasets
Chromatin data (ChIP-seq) from CD4+ T cells was downloaded from ENCODE: H3K4me1
(ENCFF112QDR, ENCFF499NFE, ENCFF989BNS), H3K9me3 (ENCFF044NLN, ENCFF736KRZ,
ENCFF844IWD, ENCFF929BPC), H3K27ac (ENCFF618IUD, ENCFF862SKP), H3K27me3
(ENCFF124QDD, ENCFF298JKA, ENCFF717ODY), H3K36me3 (ENCFF006VTQ, ENCFF169QYM,
ENCFF284PKI, ENCFF504OUW), DNAse (GSM665812, GSM665839, GSM701489, GSM701491).
Data were analyzed using Seqmonk (v0.33, http://www.bioinformatics.bbsrc.ac.uk/projects/ seq-
monk/).
We calculated expression (GSM669617) and chromatin mark abundance (the remaining ENCODE
datasets) at the integration sites as bins of 500 bp centered on the integration site (read count quan-
tification in Seqmonk: all non-duplicated reads regardless of strand, corrected per million reads
total, non-log transformed). Gene annotations were not taken into account. Thresholds for expres-
sion values (upper 1/8th, upper quarter, half, and above 0) were set to distinguish five different cate-
gories, set as the upper 1/8th of expression values (high), upper quarter–1/8th (medium), upper
half–quarter (low), lower half but above 0 (trace), 0 (silent).
CD4+ T cells activation data in Figure 5A weredownloaded from GEO (GSE60235).
Statistical analysis
Significance was analyzed by either paired t-test (GraphPad Prism) or proportion test (standard test
for the difference between proportions), also known as a two-proportion z test (https://www.med-
calc.org/calc/comparison_of_proportions.php), and specified in the manuscript.
Acknowledgements
We thank Herb Kasler for critical reading of the manuscript and help with data analysis, Giovanni
Maki, Teresa Roberts and John Carroll for graphic preparation, Gary Howard for editorial assistance,
and Veronica Fonseca for administrative assistance. EB was supported by a post-doctoral fellowship
from UCSF CFAR and a CHRP fellowship. MD was supported by a CIHR 201311MFE-321128–
179658. EV was supported by funds from NIH 1R01DA030216, 1DP1DA031126, NIH/NIAID
R01Ai117864 NIH/NIDA/1R01DA041742-01, NIH/NIDCR/1R01DE026010-01, and 5–31532. We
would also like to thank Marielle Cavrois and Herb Kasler, respectively directors of the Gladstone
and Buck Flow Cores. The Gladstone Flow Core was funded by NIH Grants P30AI027763 and S10
RR028962 and by the University of California, San Francisco-Gladstone Institute of Virology and
Immunology Center for AIDS Research (CFAR). The standards for PCR methods were made available
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 16 of 22
Research article Microbiology and Infectious Disease
with help from the University of California San Francisco-Gladstone Institute of Virology and Immu-
nology Center for AIDS Research (CFAR), an NIH-funded program (P30 AI027763), and NIH/NIAI-
DR21AI129636 for MAM. We thank the amfAR Institute for HIV Cure Research. JPS. was supported
by the Swedish Research Council (VR2015-02312) and Cancerfonden (CAN2016/576). SKP was sup-
ported by a NIGMS fund R01GM117901
Additional information
Funding
Funder Grant reference number Author
Center for AIDS Research,
University of California, San
Diego
Emilie Battivelli
Mohamed Abdel-Mohsen
California HIV/AIDS Research
Program
Emilie Battivelli
Canadian Institutes of Health
Research
201311MFE-321128-179658 Matthew S Dahabieh
National Institute of Allergy
and Infectious Diseases
R21AI129636 Mohamed Abdel-Mohsen
Svenska Forskningsra˚det For-
mas
VR2015-02312 J Peter Svensson
Cancerfonden CAN2016/576 J Peter Svensson
National Institute of General
Medical Sciences
R01GM117901 Satish K Pillai
National Institute of Allergy
and Infectious Diseases
R01Ai117864 Eric Verdin
National Institute on Drug
Abuse
1R01DA041742-01 Eric Verdin
National Institute of Dental
and Craniofacial Research
1R01DE026010-01 Eric Verdin
National Institute of Dental
and Craniofacial Research
5-31532 Eric Verdin
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Emilie Battivelli, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding
acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project
administration, Writing—review and editing; Matthew S Dahabieh, Methodology, Writing—review
and editing; Mohamed Abdel-Mohsen, Resources, Investigation, Writing—review and editing; J
Peter Svensson, Conceptualization, Resources, Data curation, Formal analysis, Validation, Writing—
original draft, Writing—review and editing; Israel Tojal Da Silva, Data curation, Software, Formal
analysis, Methodology; Lillian B Cohn, Resources, Methodology, Writing—review and editing;
Andrea Gramatica, Warner C Greene, Satish K Pillai, Resources, Writing—review and editing; Steven
Deeks, Resources; Eric Verdin, Conceptualization, Supervision, Funding acquisition, Validation,
Methodology, Writing—review and editing
Author ORCIDs
Emilie Battivelli http://orcid.org/0000-0003-3297-0231
J Peter Svensson http://orcid.org/0000-0002-5863-6250
Lillian B Cohn http://orcid.org/0000-0002-3485-8692
Steven Deeks http://orcid.org/0000-0001-6371-747X
Eric Verdin http://orcid.org/0000-0003-3703-3183
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 17 of 22
Research article Microbiology and Infectious Disease
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.34655.027
Author response https://doi.org/10.7554/eLife.34655.028
Additional files
Supplementary files
. Source data 1. Integration Sites - Source Data: List of integration sites for each donor and each
population.
DOI: https://doi.org/10.7554/eLife.34655.020
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.34655.021
Data availability
All sequencing data generated during this study are included in the Integration sites Source data file
1
References
Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney
MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012a.
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482–485.
DOI: https://doi.org/10.1038/nature11286, PMID: 22837004
Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL,
Eron JJ, Margolis DM, Perelson AS. 2012b. Immediate antiviral therapy appears to restrict resting CD4+ cell
HIV-1 infection without accelerating the decay of latent infection. PNAS 109:9523–9528. DOI: https://doi.org/
10.1073/pnas.1120248109, PMID: 22645358
Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M.
2012. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of Leukocyte Biology
92:1147–1154. DOI: https://doi.org/10.1189/jlb.0312165, PMID: 22802445
Barr SD, Ciuffi A, Leipzig J, Shinn P, Ecker JR, Bushman FD. 2006. HIV integration site selection: targeting in
macrophages and the effects of different routes of viral entry. Molecular Therapy 14:218–225. DOI: https://doi.
org/10.1016/j.ymthe.2006.03.012, PMID: 16647883
Battivelli E, Verdin E. 2018. HIVGKO: a tool to assess HIV-1 latency reversal agents in human primary CD4+ T
cells. Bio-Protocol 8:e3050. DOI: https://doi.org/10.21769/BioProtoc.3050
Besnard E, Hakre S, Kampmann M, Lim HW, Hosmane NN, Martin A, Bassik MC, Verschueren E, Battivelli E,
Chan J, Svensson JP, Gramatica A, Conrad RJ, Ott M, Greene WC, Krogan NJ, Siliciano RF, Weissman JS,
Verdin E. 2016. The mTOR complex controls HIV latency. Cell Host & Microbe 20:785–797. DOI: https://doi.
org/10.1016/j.chom.2016.11.001, PMID: 27978436
Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM,
Siliciano RF, Weinberger L, Verdin E, Ott M. 2013. BET bromodomain-targeting compounds reactivate HIV
from latency via a Tat-independent mechanism. Cell Cycle 12:452–462. DOI: https://doi.org/10.4161/cc.23309,
PMID: 23255218
Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho
YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. 2016. Defective proviruses rapidly accumulate during
acute HIV-1 infection. Nature Medicine 22:1043–1049. DOI: https://doi.org/10.1038/nm.4156, PMID: 27500724
Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective
and ineffective single agents for reversing HIV-1 latency in vivo. Nature Medicine 20:425–429. DOI: https://doi.
org/10.1038/nm.3489, PMID: 24658076
Bushman F, Lewinski M, Ciuffi A, Barr S, Leipzig J, Hannenhalli S, Hoffmann C. 2005. Genome-wide analysis of
retroviral DNA integration. Nature Reviews Microbiology 3:848–858. DOI: https://doi.org/10.1038/
nrmicro1263, PMID: 16175173
Calvanese V, Chavez L, Laurent T, Ding S, Verdin E. 2013. Dual-color HIV reporters trace a population of latently
infected cells and enable their purification. Virology 446:283–292. DOI: https://doi.org/10.1016/j.virol.2013.07.
037, PMID: 24074592
Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J. 1999. Efficacy and safety analyses of a recombinant human
immunodeficiency virus type 1 derived vector system. Gene Therapy 6:715–728. DOI: https://doi.org/10.1038/
sj.gt.3300895, PMID: 10505094
Chen H-C, Martinez JP, Zorita E, Meyerhans A, Filion GJ. 2017. Position effects influence HIV latency reversal.
Nature Structural & Molecular Biology 24:47–54. DOI: https://doi.org/10.1038/nsmb.3328
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 18 of 22
Research article Microbiology and Infectious Disease
Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early establishment of a pool of latently
infected, resting CD4(+) T cells during primary HIV-1 infection. PNAS 95:8869–8873. DOI: https://doi.org/10.
1073/pnas.95.15.8869, PMID: 9671771
Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Coffin JM, Mellors JW. 2014. Quantification of HIV-1
latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. PNAS 111:7078–
7083. DOI: https://doi.org/10.1073/pnas.1402873111, PMID: 24706775
Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann
C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC. 2015. HIV-1
integration landscape during latent and active infection. Cell 160:420–432. DOI: https://doi.org/10.1016/j.cell.
2015.01.020, PMID: 25635456
Cui Y, Iwakuma T, Chang LJ. 1999. Contributions of viral splice sites and cis-regulatory elements to lentivirus
vector function. Journal of Virology 73:6171–6176. PMID: 10364378
Dahabieh MS, Ooms M, Simon V, Sadowski I. 2013. A doubly fluorescent HIV-1 reporter shows that the majority
of integrated HIV-1 is latent shortly after infection. Journal of Virology 87:4716–4727. DOI: https://doi.org/10.
1128/JVI.03478-12, PMID: 23408629
Dahabieh MS, Ooms M, Brumme C, Taylor J, Harrigan PR, Simon V, Sadowski I. 2014. Direct non-productive
HIV-1 infection in a T-cell line is driven by cellular activation state and NFkB. Retrovirology 11:17. DOI: https://
doi.org/10.1186/1742-4690-11-17, PMID: 24502247
Dahabieh MS, Battivelli E, Verdin E. 2015. Understanding HIV latency: the road to an HIV cure. Annual Review of
Medicine 66:407–421. DOI: https://doi.org/10.1146/annurev-med-092112-152941, PMID: 25587657
Dar RD, Razooky BS, Singh A, Trimeloni TV, McCollum JM, Cox CD, Simpson ML, Weinberger LS. 2012.
Transcriptional burst frequency and burst size are equally modulated across the human genome. PNAS 109:
17454–17459. DOI: https://doi.org/10.1073/pnas.1213530109, PMID: 23064634
Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C,
Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N,
Moutschen M, et al. 2015. An in-depth comparison of latency-reversing agent combinations in various in vitro
and ex vivo hiv-1 latency models identified bryostatin-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral
gene expression. PLoS Pathogens 11:e1005063. DOI: https://doi.org/10.1371/journal.ppat.1005063,
PMID: 26225566
Daugaard M, Baude A, Fugger K, Povlsen LK, Beck H, Sørensen CS, Petersen NH, Sorensen PH, Lukas C, Bartek
J, Lukas J, Rohde M, Ja¨a¨ttela¨ M. 2012. LEDGF (p75) promotes DNA-end resection and homologous
recombination. Nature Structural & Molecular Biology 19:803–810. DOI: https://doi.org/10.1038/nsmb.2314,
PMID: 22773103
De Crignis E, Mahmoudi T. 2017. The Multifaceted Contributions of Chromatin to HIV-1 Integration,
Transcription, and Latency. International Review of Cell and Molecular Biology 328:197–252. DOI: https://doi.
org/10.1016/bs.ircmb.2016.08.006, PMID: 28069134
del Real G, Jime´nez-Baranda S, Mira E, Lacalle RA, Lucas P, Go´mez-Mouto´n C, Alegret M, Pen˜a JM, Rodrı´guez-
Zapata M, Alvarez-Mon M, Martı´nez-A C, Man˜es S. 2004. Statins inhibit HIV-1 infection by down-regulating Rho
activity. The Journal of Experimental Medicine 200:541–547. DOI: https://doi.org/10.1084/jem.20040061,
PMID: 15314078
Demeulemeester J, De Rijck J, Gijsbers R, Debyser Z. 2015. Retroviral integration: Site matters: Mechanisms and
consequences of retroviral integration site selection. BioEssays : News and Reviews in Molecular, Cellular and
Developmental Biology 37:1202–1214. DOI: https://doi.org/10.1002/bies.201500051, PMID: 26293289
Eidahl JO, Crowe BL, North JA, McKee CJ, Shkriabai N, Feng L, Plumb M, Graham RL, Gorelick RJ, Hess S,
Poirier MG, Foster MP, Kvaratskhelia M. 2013. Structural basis for high-affinity binding of LEDGF PWWP to
mononucleosomes. Nucleic Acids Research 41:3924–3936. DOI: https://doi.org/10.1093/nar/gkt074, PMID: 233
96443
Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J,
Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA,
Zeidan J, Palmer S, et al. 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected
patients on suppressive antiretroviral therapy. PLoS Pathogens 10:e1004473. DOI: https://doi.org/10.1371/
journal.ppat.1004473, PMID: 25393648
Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A,
Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR. 2015. Short-term administration of disulfiram
for reversal of latent HIV infection: a phase 2 dose-escalation study. The Lancet HIV 2:e520–e529. DOI: https://
doi.org/10.1016/S2352-3018(15)00226-X, PMID: 26614966
Ferris AL, Wu X, Hughes CM, Stewart C, Smith SJ, Milne TA, Wang GG, Shun MC, Allis CD, Engelman A,
Hughes SH. 2010. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. PNAS
107:3135–3140. DOI: https://doi.org/10.1073/pnas.0914142107, PMID: 20133638
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I,
Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La
Thangue N, et al. 2010. Selective inhibition of BET bromodomains. Nature 468:1067–1073. DOI: https://doi.
org/10.1038/nature09504, PMID: 20871596
Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 2011. Epigenetic silencing of HIV-1
by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. Journal of Virology 85:9078–9089.
DOI: https://doi.org/10.1128/JVI.00836-11, PMID: 21715480
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 19 of 22
Research article Microbiology and Infectious Disease
Gesner M, Maiti M, Grant R, Cavrois M. 2014. Fluorescence-linked antigen quantification (FLAQ) assay for fast
quantification of HIV-1 p24Gag. Bio-Protocol 4. DOI: https://doi.org/10.21769/BioProtoc.1366, PMID: 27525295
Guelen L, Pagie L, Brasset E, Meuleman W, Faza MB, Talhout W, Eussen BH, de Klein A, Wessels L, de Laat W,
van Steensel B. 2008. Domain organization of human chromosomes revealed by mapping of nuclear lamina
interactions. Nature 453:948–951. DOI: https://doi.org/10.1038/nature06947, PMID: 18463634
Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC, Margolick JB, Siliciano RF, Siliciano JD.
2004. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry
integrated HIV-1 genomes within actively transcribed host genes. Journal of Virology 78:6122–6133.
DOI: https://doi.org/10.1128/JVI.78.12.6122-6133.2004, PMID: 15163705
Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF.
2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell
155:540–551. DOI: https://doi.org/10.1016/j.cell.2013.09.020, PMID: 24243014
Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD,
Garcia JV. 2017. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral
therapy. Nature Medicine 23:638–643. DOI: https://doi.org/10.1038/nm.4319, PMID: 28414330
Iwakuma T, Cui Y, Chang LJ. 1999. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261:
120–132. DOI: https://doi.org/10.1006/viro.1999.9850, PMID: 10441560
Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, Fenton A, Melcher GP, Hildreth JE, Thompson GR,
Wong JK, Dandekar S. 2015. Synergistic reactivation of latent HIV expression by ingenol-3-Angelate, PEP005,
Targeted NF-kB signaling in combination with JQ1 Induced p-TEFb Activation. PLoS Pathogens 11:e1005066.
DOI: https://doi.org/10.1371/journal.ppat.1005066, PMID: 26225771
Jordan A, Defechereux P, Verdin E. 2001. The site of HIV-1 integration in the human genome determines basal
transcriptional activity and response to Tat transactivation. The EMBO Journal 20:1726–1738. DOI: https://doi.
org/10.1093/emboj/20.7.1726, PMID: 11285236
Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T
cells in vitro. The EMBO Journal 22:1868–1877. DOI: https://doi.org/10.1093/emboj/cdg188, PMID: 12682019
Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, Garcia
JV, Valente ST. 2017. In vivo suppression of HIV rebound by didehydro-cortistatin A, a "Block-and-Lock"
strategy for HIV-1 treatment. Cell Reports 21:600–611. DOI: https://doi.org/10.1016/j.celrep.2017.09.080,
PMID: 29045830
Kim H, Choi MS, Inn KS, Kim BJ. 2016. Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a
HSP90-dependent manner. Scientific Reports 6:28896. DOI: https://doi.org/10.1038/srep28896,
PMID: 27363520
Kumar A, Darcis G, Van Lint C, Herbein G. 2015. Epigenetic control of HIV-1 post integration latency:
implications for therapy. Clinical Epigenetics 7:103. DOI: https://doi.org/10.1186/s13148-015-0137-6,
PMID: 26405463
Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo
analysis identifies effective HIV-1 latency-reversing drug combinations. Journal of Clinical Investigation 125:
1901–1912. DOI: https://doi.org/10.1172/JCI80142, PMID: 25822022
Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G, Collins F, Shinn P, Leipzig J,
Hannenhalli S, Berry CC, Ecker JR, Bushman FD. 2006. Retroviral DNA integration: viral and cellular
determinants of target-site selection. PLoS Pathogens 2:e60. DOI: https://doi.org/10.1371/journal.ppat.
0020060, PMID: 16789841
Li Z, Guo J, Wu Y, Zhou Q. 2013. The BET bromodomain inhibitor JQ1 activates HIV latency through
antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Research 41:277–287. DOI: https://doi.org/
10.1093/nar/gks976, PMID: 23087374
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 25:402–408. DOI: https://doi.org/10.1006/meth.2001.1262,
PMID: 11846609
Lusic M, Marini B, Ali H, Lucic B, Luzzati R, Giacca M. 2013. Proximity to PML nuclear bodies regulates HIV-1
latency in CD4+ T cells. Cell Host & Microbe 13:665–677. DOI: https://doi.org/10.1016/j.chom.2013.05.006,
PMID: 23768491
Lusic M, Giacca M. 2015. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. Journal of
Molecular Biology 427:688–694. DOI: https://doi.org/10.1016/j.jmb.2014.07.022, PMID: 25073101
Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM,
Hughes SH. 2014. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of
infected cells. Science 345:179–183. DOI: https://doi.org/10.1126/science.1254194, PMID: 24968937
Maldarelli F. 2016. The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.
Journal of Clinical Investigation 126:438–447. DOI: https://doi.org/10.1172/JCI80564, PMID: 26829624
Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. 2016. Latency reversal and viral clearance to cure HIV-1. Science
353:aaf6517. DOI: https://doi.org/10.1126/science.aaf6517, PMID: 27463679
Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, Manganaro L, Pongor S, Luzzati R, Recchia A, Mavilio F,
Giacca M, Lusic M. 2015. Nuclear architecture dictates HIV-1 integration site selection. Nature 521:227–231.
DOI: https://doi.org/10.1038/nature14226, PMID: 25731161
Martı´nez-Bonet M, Clemente MI, Serramı´a MJ, Mun˜oz E, Moreno S, Mun˜oz-Ferna´ndez MA´. 2015. Synergistic
activation of latent hiv-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Scientific Reports
5:16445. DOI: https://doi.org/10.1038/srep16445, PMID: 26563568
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 20 of 22
Research article Microbiology and Infectious Disease
Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhan A. 2010.
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a
receptor independent manner. PLoS One 5:e11160. DOI: https://doi.org/10.1371/journal.pone.0011160,
PMID: 20585398
Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. 2004. Retroviral DNA
integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biology 2:E234. DOI: https://doi.
org/10.1371/journal.pbio.0020234, PMID: 15314653
Nguyen K, Das B, Dobrowolski C, Karn J. 2017. Multiple histone lysine methyltransferases are required for the
establishment and maintenance of HIV-1 latency. mBio 8:e00133-17. DOI: https://doi.org/10.1128/mBio.00133-
17, PMID: 28246360
Peden K, Emerman M, Montagnier L. 1991. Changes in growth properties on passage in tissue culture of viruses
derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185:661–672.
DOI: https://doi.org/10.1016/0042-6822(91)90537-L, PMID: 1683726
Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish
S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC. 2017. Defective HIV-1
proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral
landscape. Cell Host & Microbe 21:494–506. DOI: https://doi.org/10.1016/j.chom.2017.03.008, PMID: 284074
85
Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. 2012. Psip1/Ledgf p52 binds methylated
histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genetics 8:
e1002717. DOI: https://doi.org/10.1371/journal.pgen.1002717, PMID: 22615581
Quercioli V, Di Primio C, Casini A, Mulder LCF, Vranckx LS, Borrenberghs D, Gijsbers R, Debyser Z, Cereseto A.
2016. Comparative analysis of HIV-1 and murine leukemia virus three-dimensional nuclear distributions. Journal
of Virology 90:5205–5209. DOI: https://doi.org/10.1128/JVI.03188-15, PMID: 26962222
Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS. 2013. Eliminating the latent HIV
reservoir by reactivation strategies: advancing to clinical trials. Human Vaccines & Immunotherapeutics 9:790–
799. DOI: https://doi.org/10.4161/hv.23202, PMID: 23563519
Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S,
Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. 2014. Panobinostat, a histone
deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy:
a phase 1/2, single group, clinical trial. The Lancet HIV 1:e13–e21. DOI: https://doi.org/10.1016/S2352-3018
(14)70014-1, PMID: 26423811
Rasmussen TA, Lewin SR. 2016. Shocking HIV out of hiding: where are we with clinical trials of latency reversing
agents? Current opinion in HIV and AIDS 11:394–401. DOI: https://doi.org/10.1097/COH.0000000000000279,
PMID: 26974532
Rasmussen TA, Tolstrup M, Søgaard OS. 2016. Reversal of latency as part of a cure for HIV-1. Trends in
Microbiology 24:90–97. DOI: https://doi.org/10.1016/j.tim.2015.11.003, PMID: 26690612
Salamango DJ, Evans DA, Baluyot MF, Furlong JN, Johnson MC. 2013. Recombination can lead to spurious
results in retroviral transduction with dually fluorescent reporter genes. Journal of Virology 87:13900–13903.
DOI: https://doi.org/10.1128/JVI.02524-13, PMID: 24067983
Sanyal A, Mailliard RB, Rinaldo CR, Ratner D, Ding M, Chen Y, Zerbato JM, Giacobbi NS, Venkatachari NJ,
Patterson BK, Chargin A, Sluis-Cremer N, Gupta P. 2017. Novel assay reveals a large, inducible, replication-
competent HIV-1 reservoir in resting CD4+ T cells. Nature Medicine 23:885–889. DOI: https://doi.org/10.1038/
nm.4347, PMID: 28553933
Schro¨der AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. 2002. HIV-1 integration in the human genome
favors active genes and local hotspots. Cell 110:521–529. DOI: https://doi.org/10.1016/S0092-8674(02)00864-
4, PMID: 12202041
Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF.
2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after
virus reactivation. Immunity 36:491–501. DOI: https://doi.org/10.1016/j.immuni.2012.01.014, PMID: 22406268
Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto
LM, Pace MJ, Siliciano RF, O’Doherty U, Guatelli J, Planelles V, Bushman FD. 2013. HIV latency and integration
site placement in five cell-based models. Retrovirology 10:90. DOI: https://doi.org/10.1186/1742-4690-10-90,
PMID: 23953889
Shlyueva D, Stampfel G, Stark A. 2014. Transcriptional enhancers: from properties to genome-wide predictions.
Nature Reviews Genetics 15:272–286. DOI: https://doi.org/10.1038/nrg3682, PMID: 24614317
Singh A, Razooky B, Cox CD, Simpson ML, Weinberger LS. 2010. Transcriptional bursting from the HIV-1
promoter is a significant source of stochastic noise in HIV-1 gene expression. Biophysical Journal 98:L32–L34.
DOI: https://doi.org/10.1016/j.bpj.2010.03.001, PMID: 20409455
Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW,
Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N,
Rasmussen TA, Østergaard L, Tolstrup M. 2015. The depsipeptide romidepsin reverses HIV-1 Latency In Vivo.
PLoS Pathogens 11:e1005142. DOI: https://doi.org/10.1371/journal.ppat.1005142, PMID: 26379282
Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, Engelman AN. 2016. A critical role for alternative
polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. PNAS 113:
E1054–E1063. DOI: https://doi.org/10.1073/pnas.1524213113, PMID: 26858452
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 21 of 22
Research article Microbiology and Infectious Disease
Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis
DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C,
et al. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4
+ T cells from aviremic patients. PLoS Pathogens 9:e1003834. DOI: https://doi.org/10.1371/journal.ppat.
1003834, PMID: 24385908
Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM. 2015. H3K27 demethylation at the proviral
promoter sensitizes latent HIV to the effects of vorinostat in ex vivo cultures of resting CD4+ T cells. Journal of
Virology 89:8392–8405. DOI: https://doi.org/10.1128/JVI.00572-15, PMID: 26041287
Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, Schrijvers R, Weydert C, Battivelli E, Verdin E, Cereseto
A, Christ F, Gijsbers R, Debyser Z. 2016. LEDGIN-mediated inhibition of integrase-LEDGF/p75 interaction
reduces reactivation of residual latent HIV. EBioMedicine 8:248–264. DOI: https://doi.org/10.1016/j.ebiom.2016.
04.039, PMID: 27428435
Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI,
Frenkel LM. 2014. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to
persistent infection. Science 345:570–573. DOI: https://doi.org/10.1126/science.1256304, PMID: 25011556
Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. 2007. HIV integration site selection: analysis by massively
parallel pyrosequencing reveals association with epigenetic modifications. Genome Research 17:1186–1194.
DOI: https://doi.org/10.1101/gr.6286907, PMID: 17545577
Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. 2005. Stochastic gene expression in a lentiviral
positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169–182. DOI: https://doi.
org/10.1016/j.cell.2005.06.006, PMID: 16051143
Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J,
Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis
MG, Hattersley J, Li B, et al. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.
Nature 512:74–77. DOI: https://doi.org/10.1038/nature13594, PMID: 25042999
Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N, McCabe C, Lee MH, Frohlich I, Paik HI, Zaitlen N,
Hacohen N, Stranger B, De Jager P, Mathis D, Regev A, Benoist C. 2014. Intersection of population variation
and autoimmunity genetics in human T cell activation. Science 345:1254665. DOI: https://doi.org/10.1126/
science.1254665, PMID: 25214635
Yucha RW, Hobbs KS, Hanhauser E, Hogan LE, Nieves W, Ozen MO, Inci F, York V, Gibson EA, Thanh C, Shafiee
H, El Assal R, Kiselinova M, Robles YP, Bae H, Leadabrand KS, Wang S, Deeks SG, Kuritzkes DR, Demirci U,
et al. 2017. High-throughput Characterization of HIV-1 reservoir reactivation using a single-cell-in-droplet PCR
assay. EBioMedicine 20:217–229. DOI: https://doi.org/10.1016/j.ebiom.2017.05.006, PMID: 28529033
Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, Qu H, Walker BD, Elledge SJ, Brass AL. 2012. Reactivation
of latent HIV-1 by inhibition of BRD4. Cell Reports 2:807–816. DOI: https://doi.org/10.1016/j.celrep.2012.09.
008, PMID: 23041316
Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. 1996. A "humanized" green fluorescent protein
cDNA adapted for high-level expression in mammalian cells. Journal of Virology 70:4646–4654. PMID: 8676491
Battivelli et al. eLife 2018;7:e34655. DOI: https://doi.org/10.7554/eLife.34655 22 of 22
Research article Microbiology and Infectious Disease
